Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$5.37M$5.37M+32.4% vs Q3 2021 Net Income-$9.74M-$9.74MN/M vs Q3 2021 EPS, diluted—
Operating Income-$12,168,000N/M Operating Cash Flowderived-$8,778,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Free Cash Flowderived-$8,812,000N/M Margins · derivedOperating margin-226.6%+242.0 pt vs Q3 2021
Net margin-181.3%+226.3 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 4, 2022 · 35 d after period end